Tech Company Financing Transactions

Eureka Therapeutics Funding Round

Lyell Immunopharma and private investors joined a $45 million Series E venture round for Eureka Therapeutics. The round was announced on 3/18/2020.

Transaction Overview

Announced On
3/18/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series E
Investors

Lyell Immunopharma (Lead Investor) (Rick Klausner)

Proceeds Purpose
The Company will use proceeds from the Series E round to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS programs, including Eureka's anti-AFP ARTEMIS Phase I/II clinical trial in the United States for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 170
Emeryville, CA 94608
USA
Email Address
Overview
Eureka Therapeutics is focused on developing novel T cell immunotherapies for the treatment of solid tumors. Our unique platform is powered by TCR-like antibodies which recognize previously inaccessible cancer antigens specific for solid tumors.
Profile
Eureka Therapeutics LinkedIn Company Profile
Social Media
Eureka Therapeutics Company Twitter Account
Company News
Eureka Therapeutics News
Facebook
Eureka Therapeutics on Facebook
YouTube
Eureka Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cheng Liu
  Cheng Liu LinkedIn Profile  Cheng Liu Twitter Account  Cheng Liu News  Cheng Liu on Facebook
Chief Operating Officer
Vivien Chan
  Vivien Chan LinkedIn Profile  Vivien Chan Twitter Account  Vivien Chan News  Vivien Chan on Facebook
VP - Bus. Development
Hanzhong Li
  Hanzhong Li LinkedIn Profile  Hanzhong Li Twitter Account  Hanzhong Li News  Hanzhong Li on Facebook
VP - General Counsel
Victor Shum
  Victor Shum LinkedIn Profile  Victor Shum Twitter Account  Victor Shum News  Victor Shum on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/18/2020: CoreStack venture capital transaction
Next: 3/18/2020: Spectro Cloud venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary